In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BaroFold Inc.

Latest From BaroFold Inc.

Deals of the week: Forest and Colby dominate

Last week's biggest headline deals occupied the fields of cancer and dementia, while a host of smaller deals included several targeting infectious diseases affecting developing countries, and vaccine and manufacturing technologies were much in evidence.

Metabolic Disorders Infectious Diseases

Start-up Nuron gains preclinical amyloid beta 42 DNA vaccine for Alzheimer's

Nuron Biotech, a two-year old privately held US biologics and vaccines company, has brought in another licensing deal. It has licensed from Vitruvian BioMedical a gene-based amyloid 42 (Abeta42) vaccine that is in preclinical development for Alzheimer's disease. Nuron obtained an exclusive, worldwide licence for the vaccine and is responsible for the development and commercialisation.

Neurology Immune Disorders

Start-up Nuron snags 1st licensing deal, with Mitsubishi, and advances PhIII MS drug

Nuron Biotech, a two-year old privately held US biologics and vaccines company, has brought in its first licensing deal. It has signed an agreement with Mitsubishi Tanabe Pharma of Osaka, Japan, to commercialise its HibTiter vaccine (Haemophilus b conjugate vaccine [diphtheria CRM197 protein conjugate]) in Japan, both as a single entity and for combination product use.

Neurology Immune Disorders

Nuron Biotech Inc.

Founded by veterans of Pfizer, Nuron Biotech Inc. is developing a recombinant human interferon beta-1 free of human serum albumin and the aggregates that set off an immune response. Thus the start-up's lead candidate should not lose effectiveness or have the tolerability issues that plague existing interferon beta drugs. The company will move its agent directly into Phase III clinical trials in Europe this year.
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • BaroFold Inc.
  • Senior Management
  • Matthew Brewer, Pres. & CEO
    Christian Allan, PhD, Dir., R&D
  • Contact Info
  • BaroFold Inc.
    Phone: (303) 926-0337
    12635 E. Montview Blvd.
    Aurora, CO 80045